EUCTR2012-005694-31-PL进行中（未招募）1 期
Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study - APD-209 Eye drops phase IIa study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as diagnosed according to current clinical practice, and with symptoms appearing within less than 7 days at the time of giving informed consent will be included in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1) Known or suspected allergy to any ingredient of the IMP or placebo.
- •2) Symptoms correlating with EKC since more than 7 days.
- •3) Diagnosis of other significant disease(s) than EKC in the eye.
- •4) Diagnosis of bacterial or fungal ocular infections, as assessed by the Investigator.
- •5) Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study.
- •6) Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
- •7) Use of antiviral medications within 7 days prior to inclusion.
- •8) Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes, assessed by the Investigator as being relevant for the study.
- •9) Usage of any medication or herbal medicinal product for ocular administration at inclusion.
- •10) Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period.
- •11) Known or suspected drug abuse.
- •12) Usage of contact lenses during the study.
- •13) Participation in any other interventional clinical study within 30 days prior to inclusion.
- •14) Previous inclusion in this study.
- •15) Living together with a person who is already included in this study.
- •16) Any other reason that, in the opinion of the Investigator, makes the patient unsuitable for participation in the study.
研究者
相似试验
进行中（未招募）
不适用
Study comparing the efficacy of Eye drops containing the substance APD-209 and placebo for the treatment the a viral eye infection called Adenoviral-induced Epidemic Keratoconjunctivitis (EKC).Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKCMedDRA version: 18.1Level: LLTClassification code 10014975Term: Epidemic keratoconjunctivitisSystem Organ Class: 100000004862EUCTR2012-005694-31-DEAdenovir Pharma AB130
进行中（未招募）
不适用
Study comparing the efficacy of Eye drops containing the substance APD-209 and placebo for the treatment the a viral eye infection called Adenoviral-induced Epidemic Keratoconjunctivitis (EKC).Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKCMedDRA version: 14.1Level: LLTClassification code 10014975Term: Epidemic keratoconjunctivitisSystem Organ Class: 100000004862EUCTR2012-005694-31-SEAdenovir Pharma AB130
已完成
2 期
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)Viral ConjunctivitisNCT01977443Adenovir Pharma AB47
已完成
2 期
A Study to Evaluate the Efficacy and Safety of AD-209Hypertension, EssentialNCT05631990Addpharma Inc.221
尚未招募
1 期
ROLE OF CERTAIN TOPICAL AND SYSTEMIC AYURVEDIC DRUGS IN TONSILLITIS(TUNDIKERI).CTRI/2018/09/015625ational Institute of Ayurveda